Semaglutide Weight Loss in Columbia, MO — A Nurse Practitioner's Guide

There is a lot of noise around GLP-1 weight-loss medications right now, and not all of it is helpful. This piece is for adults in mid-Missouri who are considering a semaglutide program and want a clinician-honest picture of what the program is, who it’s right for, and where the trade-offs actually live.

LoveMeIV runs a structured, nurse-practitioner-managed weight-loss program built around compounded semaglutide, with weekly self-injection at home and a monthly home visit from the prescriber. The fee is $299 to $399 a month depending on your titration dose. The program is for adults who want a clinician-managed trial of a GLP-1 medication without the call-center experience of a national chain.

What follows is the walkthrough — what is in the program, who fits, who doesn’t, what the cadence looks like, and the things we tell every patient before they decide.

What semaglutide is, briefly

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Originally developed for type 2 diabetes (marketed as Ozempic), it received FDA approval at higher doses for chronic weight management (marketed as Wegovy). The mechanism is multi-step: it slows gastric emptying, modulates appetite signaling in the hypothalamus, improves insulin sensitivity, and reduces the food-reward loop that drives a lot of overconsumption. Patients describe the experience differently — “I forget to eat,” “food noise quieted,” “I can stop at one plate” — but the underlying biology is the same.

The published evidence base is substantial. The pivotal STEP trials (semaglutide 2.4 mg weekly, the Wegovy dose) showed mean body-weight reductions of roughly 12 to 15 percent over 68 weeks versus 2 to 3 percent in placebo arms. That is a meaningful clinical effect, larger than what we have seen historically with non-surgical interventions. It is also, importantly, an average — some patients respond strongly, some respond modestly, and a meaningful subset (roughly 10 to 15 percent in the trials) do not respond at all.

Compounded vs. brand-name — the honest version

The medication we prescribe in our program is compounded semaglutide, sourced from a licensed US compounding pharmacy. We get asked the difference often enough that it is worth answering directly.

The active molecule is the same. Semaglutide is semaglutide; the chemistry doesn’t change between a Novo Nordisk vial and a 503A vial.

The supply chain and regulatory pathway are different. Brand-name Ozempic and Wegovy are manufactured by Novo Nordisk under FDA-approved manufacturing protocols and are the only versions of the molecule that have been studied in the formal STEP and SUSTAIN trials. Compounded semaglutide is mixed by US compounding pharmacies under USP 797 sterile-compounding guidelines. Some compounded preparations include adjuvants (B12, methylcobalamin, glycine) that are not in the brand product; we use a plain semaglutide preparation in our program.

The cost is materially lower. As of mid-2026, brand-name Wegovy carries a retail list price above $1,300 per month. Compounded semaglutide generally costs $200 to $400 per month at the patient level depending on the prescriber and the pharmacy. Our program lands at the lower end of that range because we have negotiated direct sourcing with our pharmacy partners.

The regulatory environment is fluid. When the FDA-published “drug shortage” status of brand semaglutide changes, the compounding rules around it change too. We monitor this closely. If the regulatory environment shifts in a way that affects our ability to compound, we will say so to every program patient and walk them through their options.

We are not anti-brand. For some patients — particularly those with insurance coverage that meaningfully defrays the brand cost — Ozempic or Wegovy through their primary care provider is the right path. We will say so. The compounded program is for the patients for whom the cost difference is the deciding factor.

Who the program is for

Three patient profiles where the program is a good fit:

The clinically eligible adult who wants real prescriber continuity

Adults with a body mass index of 30 or higher, or 27 or higher with a related condition (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, fatty liver), are clinically eligible for GLP-1 weight management. Many have already tried lifestyle interventions and want a structured medical trial. The program fits when they also want the prescriber to be the same clinician across the program — not a different telehealth provider every month, not a national chain’s rotating roster.

The patient who has been on a GLP-1 before and wants continuity of care

We see meaningful demand from patients who started semaglutide elsewhere — sometimes through a primary care provider whose practice has changed, sometimes through a national chain whose service they outgrew — and who want a single mid-Missouri clinician they can call. We accept transfers gladly and review the prior dose history, prior labs, and prior side-effect profile in the first visit.

The patient who wants the program to be local

Mid-Missouri is not New York. The handful of national-chain weight-loss telehealth services that operate here often route patients to a clinician they will never meet in person. For patients who prefer a relationship with a clinician who knows the town, who knows the labs, and who can come to the house, the program is the local option.

Who the program is not for

Equally important. Five patient profiles where we will not start the program:

Patients with contraindications

Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN-2), pancreatitis (acute or chronic), severe gastroparesis, or known hypersensitivity to semaglutide. We screen for all of these at intake.

Pregnant or breastfeeding patients

GLP-1 agonists are not recommended in pregnancy, and effective contraception should be in place before starting. If you are planning pregnancy in the next 6 to 12 months, the program is not the right fit; we will say so.

Active eating disorders

Anorexia, bulimia, or binge-eating disorder in the active phase is an absolute contraindication. Semaglutide’s appetite-suppressing mechanism is precisely the wrong tool in those situations and can cause real harm. We will refer to an eating-disorder-specialist provider.

Patients seeking cosmetic-only weight loss without a medical indication

If your BMI is below 27 and you don’t have a related medical condition, you are not clinically eligible for GLP-1 weight management as currently understood. We will tell you that. The “lose the last ten pounds” use case is not what this medication is for, and using it that way carries risks (loss of lean mass, GI side effects without clinical benefit, sourcing risks if you go elsewhere) that don’t justify the gain.

Patients who want a no-monitoring path

We require monthly check-ins, baseline and follow-up labs, and a real conversation about trajectory at month 3 and month 6. If you want to “just get the medication” without the monitoring, we are not the right practice. Several lower-touch telehealth services exist that will mail medication after a brief intake; we are not one of them.

What the monthly cadence actually looks like

A typical month in the program runs like this:

Week 1. You self-administer the weekly injection at home — subcutaneous, into the abdomen or the thigh. The first month begins at 0.25 mg weekly (the standard starter dose for tolerability), and we titrate up over the following months based on response and tolerance.

Weeks 2–3. Continued weekly injection, self-administered. You log any side effects in a short weekly check-in form. LoveMeIV reviews flagged check-ins within 24 hours.

Week 4. The monthly LoveMeIV visit. We come to your home in Columbia, Jefferson City, or anywhere inside our 35-mile service radius. Vitals, weight, body composition (where available), a structured review of side effects, an honest conversation about trajectory. Labs every three months at a draw site close to you — we send the order, the lab draws, LoveMeIV reviews and discusses results at the next visit.

Months 2 through 6. Slow titration to a therapeutic dose if tolerated. Most patients land at 1.0 to 1.7 mg weekly depending on response. Patients who reach a satisfying weight and want to maintain rather than continue losing transition to a lower maintenance dose; patients who want to keep losing continue titrating.

Month 6 and beyond. A structured re-evaluation at month 6 of trajectory, side effects, lab trends, and goals. Some patients continue the program; some transition off; some shift to maintenance at a lower dose. The choice is theirs and the conversation is real.

The trade-offs the marketing won’t tell you

A few honest points that get glossed over in the GLP-1 marketing space:

Loss of lean mass is real. Roughly 25 to 40 percent of weight lost on GLP-1 medications is lean mass, not fat — the same range as other weight-loss interventions. This is why we strongly recommend resistance training and adequate protein intake (1.2 to 1.6 grams per kilogram of goal-weight body weight per day) for every program patient. The medication does not care whether the weight comes off your hips or your quads; you have to.

Side effects are real, especially in the first two weeks of each titration step. Nausea is the most common; constipation is common; reflux is occasional. Most settle. The minority that don’t settle are a clinical conversation, not a “tough it out” conversation.

Discontinuation often produces weight regain. This is the part of the GLP-1 conversation people are most reluctant to be honest about. The published data show that patients who stop semaglutide often regain a meaningful fraction of the weight they lost over the following 12 months. The program fits best when patients understand this going in and have a thoughtful position on maintenance vs. discontinuation.

This is not a substitute for the underlying work. GLP-1 medications shift the metabolic environment in a meaningful way; they do not fix sleep, stress, sedentary lifestyle, or disordered eating. The patients who get the most out of the program are usually the ones who use it as a window — six to twelve months of meaningfully easier appetite regulation — to build the sleep, training, and food habits that compound long after the medication.

Booking

The program intake starts with a phone call or an online intake form at book.lovemeiv.com. The first visit is a 60-minute home consultation: a structured medical history, a review of any prior labs, an honest conversation about goals and constraints, and a yes-or-no on starting. We do not charge a separate consultation fee inside the program — the first visit is included.

If the answer is no — if there is a contraindication, if the BMI doesn’t support eligibility, if the timing isn’t right — we will say so on the first visit and refund any program fee already paid. A bad fit is not a sale.

If the answer is yes, the medication arrives, the weekly cadence starts, and the next month’s visit is on the calendar. The same nurse practitioner runs every visit. The phone number is on every page; pick it up if any of this is the conversation you want to have.